eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
12 hedge funds and large institutions have $3.41K invested in eFFECTOR Therapeutics, Inc. Warrant in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding
Funds holding: 12 → 12 (0)
99% less capital invested
Capital invested by funds: $355K → $3.41K (-$351K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.34K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$2.17K |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$290 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$1.03K |
| 2 |
ICM
III Capital Management
Boca Raton,
Florida
|
-$180 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Aristeia Capital
Greenwich,
Connecticut
| $1.63K | -$1.03K | -29,800 | -2% |
|
2
Goldman Sachs
New York
| $757 | – | – | – |
|
|
WA
3
Whitebox Advisors
Minneapolis,
Minnesota
| $358 | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $241 | +$6.34K | +183,763 | +1,094% |
|
|
MI
5
MMCAP International
Grand Cayman,
Cayman Islands
| $175 | – | – | – |
|
|
PA
6
Parallel Advisors
San Francisco,
California
| $77 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $64 | +$2.17K | +63,001 | +9,783% |
|
|
ICM
8
III Capital Management
Boca Raton,
Florida
| $45 | -$180 | -5,216 | -12% |
|
|
TCM
9
Tenor Capital Management
New York
| $40 | – | – | – |
|
|
WAM
10
Wolverine Asset Management
Chicago,
Illinois
| $21 | +$290 | +8,410 | +86% |
|
EFTRW Hedge Fund Activity: Q2 2024 in Review
12 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q2 2024, worth a combined $3.41K — down 99% from $355K a quarter earlier.
Fund positioning in EFTRW was balanced in Q2 2024: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $6.34K. The largest seller was Aristeia Capital, cutting an estimated $1.03K.
- 12 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $3.41K of eFFECTOR Therapeutics, Inc. Warrant stock for Q2 2024, down 99% quarter-over-quarter.
- 0 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q2 2024 and 0 closed out.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q2 2024 was Susquehanna International Group, an estimated $6.34K added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q2 2024 was Aristeia Capital, an estimated $1.03K sold.
Based on aggregated 13F filings for Q2 2024.